Investigators assessed silmitasertib monotherapy in patients who had failed first-line hedgehog pathway inhibitors, with 27.3% also failing second-line PD-1 inhibitors such as cemiplimab (Libtayo) or ...

Libtayo shows robust growth in specific cancers, although it faces stiff competition in broader indications, highlighting Regeneron’s ability to develop blockbuster drugs. Regeneron appears ...

You may take cemiplimab (Libtayo), nivolumab (Opdivo), or pembrolizumab (Keytruda). Atezolizumab (Tecentriq) and durvalumab (Imfinzi) may also be given to treat certain types of NSCLC with a ...

How does histology, staging and ECOG performance status play into treatment considerations at your practice today, and how do these factors compare to the baseline characteristics of this study? What ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945’s potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

and cemiplimab (Libtayo), an anti–PD-1 agent, in patients with advanced melanoma. 1 The first-in-human, phase 1, open-label, dose-escalation and cohort expansion trial sought to evaluate the safety ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

Regeneron's main product is Duxipent, an autoimmune disease drug. It sells Libtayo, a cancer drug that recently got approved for a new medical indication. Both drugs are sold through a partnership ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...